Santa Monica, CA - GoodRx Holdings Inc., a leading consumer-focused digital healthcare platform in the United States, today announced the launch of its initial public offering of 34,615,384 shares of its Class A common stock. The offering consists of 23,422,727 shares of Class A common stock offered by GoodRx and 11,192,657 shares of Class A common stock to be sold by certain of GoodRx’s existing stockholders. GoodRx will not receive any proceeds from the sale of the shares by the selling shareholders. The underwriters will have a 30-day option to buy an additional 5,192,307 shares of Class A common stock from GoodRx at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is currently expected to be between $24 and $28 per share. GoodRx intends to list its Class A common stock on the NASDAQ Global Select Market, under the ticker symbol “GDRX.”
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Barclays will act as lead bookrunners for the proposed offering. BofA Securities, Citigroup, Credit Suisse Securities (USA) LLC, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, and Evercore ISI will act as additional bookrunners, and Citizens Capital Markets, KKR Capital Markets, LionTree Advisors, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus & Co., LLC and Ramirez & Co., Inc. will act as co-managers for the proposed offering.
In addition to the shares of Class A common stock sold in the public offering, GoodRx announced that entities affiliated with Silver Lake, an existing stockholder, have agreed, subject to customary closing conditions, to purchase a number of shares of Class A common stock with an aggregate purchase price of $100 million at a price equal to the initial public offering price. At an assumed initial public offering price of $26.00 per share, which is the midpoint of the estimated offering price range, Silver Lake would purchase 3,846,153 shares of our Class A common stock. The sale of these shares will not be registered under the Securities Act of 1933, as amended.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing email@example.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, collect telephone: 1-212-834-4533, or by emailing at firstname.lastname@example.org; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at email@example.com or telephone at 1-888-603-5847.
A registration statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
GoodRx’s mission is to help Americans get the healthcare they need at a price they can afford. GoodRx’s leading digital platform for consumer healthcare products and services connects consumers with affordable and convenient prescriptions and medical care, including telehealth, mail order prescriptions, doctor visits, and lab tests. GoodRx has helped Americans save over $20 billion since 2011 and was the #1 most downloaded medical app in the last three years.